SSX2IP and nasopharyngeal carcinoma: While there are no reports on SSX2IP mutations in RCC, a study on nasopharyngeal carcinoma has revealed that SSX2IP overexpression is associated with disease specific survival (hazard ratio: 4.290; 95% confidence interval: 2.271–8.102; p < 0.001) and distant metastasis-free survival (HR: 4.159; 95% CI: 2.072–8.345; p < 0.001) [70].